Cite
Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.
MLA
Kim, Minhee, et al. “Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.” Journal of Clinical Medicine, vol. 13, no. 12, June 2024, p. 3434. EBSCOhost, https://doi.org/10.3390/jcm13123434.
APA
Kim, M., Kang, J. E., & Park, Y. G. (2024). Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 13(12), 3434. https://doi.org/10.3390/jcm13123434
Chicago
Kim, Minhee, Ji Eon Kang, and Young Gun Park. 2024. “Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.” Journal of Clinical Medicine 13 (12): 3434. doi:10.3390/jcm13123434.